ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 05, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2023 (the “Grant Date”), ORIC granted a total of 29,800 non-qualified stock options and 4,980 restricted stock units to two new non-executive employees who began their employment with ORIC in April 2023.
Related news for (ORIC)
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Don’t Miss Out: MoBot’s Latest Stock Updates 05/29/25 09:00 AM
- Today’s Top Performers: MoBot’s Market Review 05/28/25 07:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 05/28/25 06:00 PM
- Today’s Top Performers: MoBot’s Market Review 05/28/25 05:00 PM